A SIMPLE KEY FOR HEMGENIX UNVEILED

Variety of qualified clients: CDEC reviewed the uncertainty in the quantity of people with reasonably intense to severe hemophilia B in Canada eligible for etranacogene dezaparvovec. Scientific experts consulted by CADTH indicated that some patients who are categorised as possessing moderate or reasonable illness could have a severe bleeding phenot